Correction: Characterization of chitosan- and β-cyclodextrin-modified forms of magnesium-doped hydroxyapatites as enhanced carriers for levofloxacin: loading, release, and anti-inflammatory properties

TL;DR

This paper corrects a previous study on modified hydroxyapatites for drug delivery and anti-inflammatory effects.

Contribution

The paper provides corrections to a prior publication on magnesium-doped hydroxyapatites modified with chitosan and β-cyclodextrin.

Findings

The paper corrects errors in the original study's characterization of drug carriers.

Modifications to hydroxyapatites were found to influence drug loading and release properties.

Anti-inflammatory properties of the modified forms were previously reported.

Abstract

Correction for ‘Characterization of chitosan- and β-cyclodextrin-modified forms of magnesium-doped hydroxyapatites as enhanced carriers for levofloxacin: loading, release, and anti-inflammatory properties' by May N. Bin Jumah et al., RSC Adv., 2024, 14, 16991–17007, https://doi.org/10.1039/d4ra02144d.